Q-omics provides the consensus-scored SYT17 profile across patient tissues and cancer cell-line models. SYT17 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, SYT17 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, SYT17 RNA expression shows 17,235 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight MESO, KIRC, and THYM as cancer lineages where SYT17 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SYT17 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SYT17 survival associations across molecular data types. SYT17 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SYT17 RNA expression–survival associations across cancer types. High SYT17 expression shows unfavorable associations in LAML, HNSC and COAD, but favorable associations in MESO, THYM and SKCM. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .006). Together, the overview and detailed table identify MESO as the clearest survival context for SYT17 RNA expression.
This table summarizes SYT17 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SYT17. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SYT17 shows lower tumor expression in KIRC and LUSC and higher tumor expression in UCEC, BRCA, KICH and BLCA. The KIRC box plot shows higher SYT17 RNA expression in normal versus tumor tissue (log2 FC = −1.406, t-test p < 0.001).
This table shows molecular features associated with SYT17 in patient tissues and cancer cell lines. In patient samples, SYT17 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, SYT17 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Lymphoma.
